Litcius/Paper detail

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Afsáneh Alavi, Z. Reguiaï, Alice B. Gottlieb, Falk G. Bechara, C. Paul, Evangelos J. Giamarellos Bourboulis, A. Villani, Andreas Schwinn, Franziska Ruëff, Larisha Pillay Ramaya, Adam Reich, Inês Lobo, Rodney Sinclair, Thierry Passeron, Antonio Martorell, Pedro Mendes‐Bastos, Georgios Kokolakis, Pierre‐André Bécherel, Magdalena B. Wozniak, Angela Llobet Martinez, Xiaoling Wei, Lorenz Uhlmann, Anna Passera, Deborah Keefe, Ruvie Martin, Clarice Field, Li Chen, Marc Vandemeulebroecke, Shoba Ravichandran, Elisa Muscianisi

2023The Lancet302 citationsDOI

Topics & Concepts

Hidradenitis suppurativaMedicinePlaceboSecukinumabClinical endpointClinical trialSurgeryRandomized controlled trialDermatologyInternal medicinePsoriasisDiseasePsoriatic arthritisAlternative medicinePathologyHidradenitis Suppurativa and TreatmentsAcne and Rosacea Treatments and EffectsAnorectal Disease Treatments and Outcomes
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials | Litcius